BLRX BioLineRx Ltd.

3.1
-0.05  -2%
Previous Close 3.15
Open 3.14
Price To Book 0.73
Market Cap 30,551,446
Shares 9,855,305
Volume 19,273
Short Ratio
Av. Daily Volume 62,071

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b/2 data due late 2019 or early 2020.
BL-8040 in combination with TECENTRIQ (atezolizumab)
Non-small cell lung cancer (NSCLC)
Phase 1/2 initiation announced October 18, 2017.
BL-8040 and atezolizumab
Gastric Cancer
Phase 2 data presented at EHA June 15, 2018.
BL-8040
Stem-cell mobilization for allogeneic transplantation
Phase 1/2 initiation announced September 26, 2017.
BL-8040 in combination with atezolizumab - BATTLE
Acute myeloid leukemia (AML)
Phase 2a data due 2H 2019.
BL-8040 in combination with KEYTRUDA
Pancreatic cancer
Phase 2 top-line data due 2H 2019 with PFS data due mid-2020.
BL-8040 in combination with KEYTRUDA - COMBAT trial
Pancreatic cancer
Phase 2b interim data due 2H 2019.
BL-8040
Consolidation treatment for AML cancer patients
Phase 3 top-line data due 2H 2020.
BL-8040 GENESIS
Stem-cell mobilization for autologous transplantation
Phase 2 data released March 2016. Full set of data presented September 8, 2016
BL-8040
Acute myeloid leukemia (AML) cancer relapsed and refractory
Phase 1/2 initial safety data 2H 2019. Efficacy data due YE 2020.
AGI-134
Solid tumors
Phase 1b/2 data due late 2019 or early 2020.
BL-8040 in combination with TECENTRIQ (atezolizumab) and PEGPH20
Pancreatic cancer

Latest News

  1. BioLineRx Reports Second Quarter 2019 Financial Results and Provides Corporate Update
  2. Tenet Healthcare (THC) Q2 Earnings: What's in the Cards?
  3. BioLineRx to Report Second Quarter 2019 Results on August 6, 2019
  4. BioLineRx Announces Change in Ratio of American Depositary Shares to Ordinary Shares
  5. BioLineRx to Present at the JMP Securities 2019 Life Sciences Conference
  6. BioLineRx (BLRX) Moves to Buy: Rationale Behind the Upgrade
  7. BioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate Update
  8. BioLineRx to Report First Quarter 2019 Results on May 14, 2019
  9. BioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid Tumors
  10. Biotech News, What Milestones and Catalysts Could Drive BioLineRx Shares in 2019
  11. BioLineRx Reports Year End 2018 Financial Results and Provides Corporate Update
  12. Four Tech Stocks Sparking Activity on Wednesday
  13. BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients
  14. BioLineRx to Report Annual 2018 Results on March 28, 2019
  15. BioLineRx to Present at the 29th Annual Oppenheimer Healthcare Conference
  16. BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants
  17. BioLineRx Announces Pricing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants
  18. Biotech on the Brink of Breaking Out